NCT01258816 - The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions

Relapsed/Refractory AML

Interventions

DRUG

Elacytarabine for infusion

Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.

Trial Locations (6)

Hospital San Pedro Alcantara, Cáceres

ICO - Hospital Duran i Reynals, Barcelona

Hospital General de la Vall d' Hebron, Barcelona

Brighton & Sussex University Hospitals NHS Trust, Brighton

University Hospital of Wales, Cardiff, Cardiff

St Bartholomew's Hospital, London